Literature DB >> 28045025

Interferon epsilon promotes HIV restriction at multiple steps of viral replication.

Albert Garcia-Minambres1,2, Sahar G Eid1,2, Niamh E Mangan3,4, Corinna Pade1,2, San S Lim3,4, Antony Y Matthews3,4, Nicole A de Weerd3,4, Paul J Hertzog3,4, Johnson Mak1,2.   

Abstract

Interferon epsilon (IFNɛ) is a type I IFN that is expressed constitutively in the female reproductive tract (FRT), and contributes to protection in models of sexually transmitted infections. Using multiple cell systems, including reporter cell lines and activated peripheral blood lymphocytes (PBLs), we show that recombinant IFNɛ impairs HIV infection at stage(s) post HIV entry and up to the translation of viral proteins. Consistent with this, IFNɛ upregulated a number of host cell restriction factors that block HIV at these stages of the replication cycle. The potency of IFNɛ induction of these HIV restriction factors was comparable to conventional type I IFNs, namely IFNα and IFNβ. IFNɛ also significantly reduced the infectivity of progeny virion particles likely by inducing expression of HIV restriction factors, such as IFITM3, which act at that stage of infection. Thus, our data demonstrate that human IFNɛ suppresses HIV replication at multiple stages of infection.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28045025     DOI: 10.1038/icb.2016.123

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  41 in total

1.  Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.

Authors:  C Aiken
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Evidence of Sexual Transmission of Zika Virus.

Authors:  Eric D'Ortenzio; Sophie Matheron; Yazdan Yazdanpanah; Xavier de Lamballerie; Bruno Hubert; Géraldine Piorkowski; Marianne Maquart; Diane Descamps; Florence Damond; Isabelle Leparc-Goffart
Journal:  N Engl J Med       Date:  2016-04-13       Impact factor: 91.245

3.  The mucosal expression pattern of interferon-ε in rhesus macaques.

Authors:  Andrew Demers; Guobin Kang; Fungrui Ma; Wuxun Lu; Zhe Yuan; Yue Li; Mark Lewis; Edmundo N Kraiselburd; Luis Montaner; Qingsheng Li
Journal:  J Leukoc Biol       Date:  2014-08-19       Impact factor: 4.962

Review 4.  Intrinsic host restrictions to HIV-1 and mechanisms of viral escape.

Authors:  Viviana Simon; Nicolin Bloch; Nathaniel R Landau
Journal:  Nat Immunol       Date:  2015-06       Impact factor: 25.606

5.  Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies.

Authors:  Lauren J Ralph; Sandra I McCoy; Karen Shiu; Nancy S Padian
Journal:  Lancet Infect Dis       Date:  2015-01-09       Impact factor: 25.071

6.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

7.  Progesterone implants enhance SIV vaginal transmission and early virus load.

Authors:  P A Marx; A I Spira; A Gettie; P J Dailey; R S Veazey; A A Lackner; C J Mahoney; C J Miller; L E Claypool; D D Ho; N J Alexander
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

8.  Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays.

Authors:  David C Montefiori
Journal:  Curr Protoc Immunol       Date:  2005-01

9.  HIV-1-negative female sex workers sustain high cervical IFNɛ, low immune activation, and low expression of HIV-1-required host genes.

Authors:  S A Abdulhaqq; C Zorrilla; G Kang; X Yin; V Tamayo; K E Seaton; J Joseph; S Garced; G D Tomaras; K A Linn; A S Foulkes; L Azzoni; M VerMilyea; C Coutifaris; A V Kossenkov; L Showe; E N Kraiselburd; Q Li; L J Montaner
Journal:  Mucosal Immunol       Date:  2015-11-11       Impact factor: 7.313

10.  Prevention of SHIV transmission by topical IFN-β treatment.

Authors:  R S Veazey; H A Pilch-Cooper; T J Hope; G Alter; A M Carias; M Sips; X Wang; B Rodriguez; S F Sieg; A Reich; P Wilkinson; M J Cameron; M M Lederman
Journal:  Mucosal Immunol       Date:  2016-02-03       Impact factor: 7.313

View more
  11 in total

1.  Defining the distinct, intrinsic properties of the novel type I interferon, IFNϵ.

Authors:  Sebastian A Stifter; Antony Y Matthews; Niamh E Mangan; Ka Yee Fung; Alexander Drew; Michelle D Tate; Tatiana P Soares da Costa; Daniel Hampsey; Jemma Mayall; Phil M Hansbro; Albert Garcia Minambres; Sahar G Eid; Johnson Mak; Judy Scoble; George Lovrecz; Nicole A deWeerd; Paul J Hertzog
Journal:  J Biol Chem       Date:  2017-11-29       Impact factor: 5.157

2.  Expanding role for type I Interferons in restricting HIV growth.

Authors:  Stephen J Kent; Anthony D Kelleher
Journal:  Immunol Cell Biol       Date:  2017-04-25       Impact factor: 5.126

3.  Human interferon-ϵ and interferon-κ exhibit low potency and low affinity for cell-surface IFNAR and the poxvirus antagonist B18R.

Authors:  Bethany D Harris; Jessica Schreiter; Marc Chevrier; Jarrat L Jordan; Mark R Walter
Journal:  J Biol Chem       Date:  2018-08-31       Impact factor: 5.157

Review 4.  Human Immunodeficiency Virus 1 and Type I Interferons-Where Sex Makes a Difference.

Authors:  Susanne Maria Ziegler; Marcus Altfeld
Journal:  Front Immunol       Date:  2017-09-28       Impact factor: 7.561

Review 5.  Manipulation of Mononuclear Phagocytes by HIV: Implications for Early Transmission Events.

Authors:  Kirstie Melissa Bertram; Orion Tong; Caroline Royle; Stuart Grant Turville; Najla Nasr; Anthony Lawrence Cunningham; Andrew Nicholas Harman
Journal:  Front Immunol       Date:  2019-09-24       Impact factor: 7.561

6.  Diverse effects of interferon alpha on the establishment and reversal of HIV latency.

Authors:  Renée M Van der Sluis; Jennifer M Zerbato; Jake W Rhodes; Rachel D Pascoe; Ajantha Solomon; Nitasha A Kumar; Ashanti I Dantanarayana; Surekha Tennakoon; Jérémy Dufloo; James McMahon; Judy J Chang; Vanessa A Evans; Paul J Hertzog; Martin R Jakobsen; Andrew N Harman; Sharon R Lewin; Paul U Cameron
Journal:  PLoS Pathog       Date:  2020-02-28       Impact factor: 6.823

Review 7.  Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome.

Authors:  Carolina Scagnolari; Guido Antonelli
Journal:  Cytokine Growth Factor Rev       Date:  2018-03-16       Impact factor: 7.638

8.  Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2.

Authors:  Manisha Pandey; Victoria Ozberk; Sharareh Eskandari; Ahmed O Shalash; Michael A Joyce; Holly A Saffran; Christopher J Day; Ailin Lepletier; Belinda L Spillings; Jamie-Lee Mills; Ainslie Calcutt; Fan Fan; James T Williams; Danielle I Stanisic; Laetitia Hattingh; John Gerrard; Mariusz Skwarczynski; Johnson Mak; Michael P Jennings; Istvan Toth; D Lorne Tyrrell; Michael F Good
Journal:  Clin Transl Immunology       Date:  2021-03-07

9.  Complement Receptor 3 Mediates HIV-1 Transcytosis across an Intact Cervical Epithelial Cell Barrier: New Insight into HIV Transmission in Women.

Authors:  Christopher J Day; Rachael L Hardison; Belinda L Spillings; Jessica Poole; Joseph A Jurcisek; Johnson Mak; Michael P Jennings; Jennifer L Edwards
Journal:  mBio       Date:  2022-01-11       Impact factor: 7.867

10.  Converging roads: the latest science from the 2017 IAS HIV Cure and Cancer Forum.

Authors:  Genevieve E Martin; José Alcami; Jean-Phillipe Spano; Anna Laura Ross
Journal:  J Virus Erad       Date:  2017-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.